TEMAZEPAM OPTIONS

nirmatrelvir will increase the degree or outcome of triazolam by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Contraindicated.Stay clear of concomitant utilization of tucatinib with CYP3A substrates, where negligible concentration improvements might bring on severe or daily life-threatening toxicities. If unavoidable, minimize CYP3A subst